Brokers Offer Predictions for Aimmune Therapeutics, Inc.’s FY2019 Earnings (NASDAQ:AIMT)

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) – Equities researchers at Cantor Fitzgerald issued their FY2019 earnings estimates for Aimmune Therapeutics in a research report issued on Monday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner expects that the biotechnology company will post earnings of ($2.17) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $55.00 price objective on the stock.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09.

A number of other research analysts also recently weighed in on AIMT. Credit Suisse Group set a $45.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday. BidaskClub downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Robert W. Baird started coverage on Aimmune Therapeutics in a research note on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 price objective for the company. Finally, ValuEngine downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $55.43.

Aimmune Therapeutics (AIMT) traded up $0.78 during mid-day trading on Thursday, reaching $39.43. The company had a trading volume of 370,464 shares, compared to its average volume of 392,144. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $40.00. The firm has a market cap of $2,010.00 and a P/E ratio of -16.85.

In related news, CEO Stephen George Dilly sold 1,154 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $26.24, for a total transaction of $30,280.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Douglas T. Sheehy sold 47,425 shares of the stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $34.44, for a total value of $1,633,317.00. Following the sale, the insider now directly owns 34,300 shares of the company’s stock, valued at $1,181,292. The disclosure for this sale can be found here. Over the last three months, insiders sold 137,946 shares of company stock valued at $4,991,189. Company insiders own 17.59% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC increased its position in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 499 shares during the last quarter. Legal & General Group Plc increased its position in shares of Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 1,634 shares during the last quarter. American International Group Inc. increased its position in shares of Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock valued at $585,000 after acquiring an additional 1,764 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Aimmune Therapeutics by 3.4% during the third quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock valued at $1,519,000 after acquiring an additional 2,025 shares during the last quarter. Finally, Daiwa SB Investments Ltd. increased its position in shares of Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 2,245 shares during the last quarter. 73.34% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/01/13/aimmune-therapeutics-inc-expected-to-post-fy2019-earnings-of-2-17-per-share-aimt.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply